Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 138,602 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 138,602 shares of the firm’s stock in a transaction that occurred on Wednesday, October 8th. The shares were sold at an average price of $16.20, for a total transaction of $2,245,352.40. Following the completion of the sale, the chief executive officer directly owned 1,504,959 shares of the company’s stock, valued at approximately $24,380,335.80. This represents a 8.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Eric Venker also recently made the following trade(s):

• On Monday, October 6th, Eric Venker sold 171,396 shares of Roivant Sciences stock. The shares were sold at an average price of $16.34, for a total transaction of $2,800,610.64.
• On Tuesday, October 7th, Eric Venker sold 355,161 shares of Roivant Sciences stock. The shares were sold at an average price of $16.15, for a total transaction of $5,735,850.15.
• On Tuesday, September 23rd, Eric Venker sold 611,000 shares of Roivant Sciences stock. The shares were sold at an average price of $14.83, for a total transaction of $9,061,130.00.
• On Monday, September 22nd, Eric Venker sold 416,182 shares of Roivant Sciences stock. The shares were sold at an average price of $14.99, for a total transaction of $6,238,568.18.
• On Friday, September 19th, Eric Venker sold 683,818 shares of Roivant Sciences stock. The shares were sold at an average price of $14.95, for a total transaction of $10,223,079.10.
• On Wednesday, August 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.72, for a total transaction of $1,172,000.00.
• On Monday, July 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.52, for a total transaction of $1,152,000.00.

Roivant Sciences Stock Performance

ROIV opened at $16.03 on Thursday. The company has a fifty day moving average price of $13.26 and a two-hundred day moving average price of $11.71. Roivant Sciences Ltd. has a 52 week low of $8.73 and a 52 week high of $16.79. The firm has a market capitalization of $10.95 billion, a PE ratio of -22.90 and a beta of 1.20.

Wall Street Analysts Forecast Growth

A number of analysts have commented on ROIV shares. HC Wainwright lifted their target price on shares of Roivant Sciences from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Thursday, September 18th. Jefferies Financial Group lifted their target price on shares of Roivant Sciences from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Thursday, September 18th. Citigroup started coverage on shares of Roivant Sciences in a report on Tuesday, September 2nd. They set a “buy” rating and a $16.00 target price for the company. Bank of America lifted their target price on shares of Roivant Sciences from $12.00 to $16.50 and gave the stock a “neutral” rating in a report on Thursday, September 18th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Roivant Sciences from $16.00 to $20.00 and gave the company an “overweight” rating in a report on Thursday, September 18th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Roivant Sciences currently has an average rating of “Moderate Buy” and an average target price of $19.94.

Hedge Funds Weigh In On Roivant Sciences

Several institutional investors and hedge funds have recently made changes to their positions in the company. CWM LLC grew its holdings in shares of Roivant Sciences by 44.6% in the 2nd quarter. CWM LLC now owns 2,984 shares of the company’s stock valued at $34,000 after buying an additional 920 shares during the period. Parallel Advisors LLC lifted its position in Roivant Sciences by 80.5% in the 1st quarter. Parallel Advisors LLC now owns 2,485 shares of the company’s stock valued at $25,000 after acquiring an additional 1,108 shares in the last quarter. M&T Bank Corp lifted its position in Roivant Sciences by 10.2% in the 2nd quarter. M&T Bank Corp now owns 12,802 shares of the company’s stock valued at $144,000 after acquiring an additional 1,181 shares in the last quarter. GAMMA Investing LLC lifted its position in Roivant Sciences by 16.6% in the 3rd quarter. GAMMA Investing LLC now owns 9,302 shares of the company’s stock valued at $141,000 after acquiring an additional 1,324 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in Roivant Sciences by 9.1% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 17,110 shares of the company’s stock valued at $173,000 after acquiring an additional 1,434 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.